Prudential Financial Inc. Sells 12,077 Shares of Humana Inc. (NYSE:HUM)

Prudential Financial Inc. lowered its stake in Humana Inc. (NYSE:HUM) by 10.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 101,108 shares of the insurance provider’s stock after selling 12,077 shares during the period. Prudential Financial Inc. owned approximately 0.08% of Humana worth $25,652,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HUM. Vanguard Group Inc. boosted its holdings in shares of Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock worth $3,254,899,000 after purchasing an additional 1,751,857 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Humana in the fourth quarter worth $10,629,000. Sei Investments Co. boosted its stake in Humana by 16.3% during the fourth quarter. Sei Investments Co. now owns 86,472 shares of the insurance provider’s stock worth $21,937,000 after buying an additional 12,142 shares during the period. American Century Companies Inc. increased its position in Humana by 8.8% during the fourth quarter. American Century Companies Inc. now owns 12,655 shares of the insurance provider’s stock valued at $3,211,000 after acquiring an additional 1,027 shares during the last quarter. Finally, Mizuho Securities USA LLC lifted its holdings in shares of Humana by 46.2% in the 4th quarter. Mizuho Securities USA LLC now owns 11,412 shares of the insurance provider’s stock worth $2,895,000 after acquiring an additional 3,605 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Down 1.3 %

HUM opened at $270.27 on Thursday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market cap of $32.62 billion, a price-to-earnings ratio of 27.16, a PEG ratio of 2.05 and a beta of 0.57. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The stock has a fifty day moving average price of $270.63 and a 200-day moving average price of $274.97.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.31%. Humana’s dividend payout ratio (DPR) is 35.58%.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.37% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on HUM shares. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Barclays increased their price target on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Morgan Stanley cut their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. StockNews.com downgraded Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 18th. Finally, Truist Financial upped their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Eighteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.